Results 151 to 160 of about 23,087 (229)

Impact of clinical pharmacist-led interventions on denosumab adherence. [PDF]

Arch Osteoporos
Zuschnitt A, Lightheart E, Myers J, Khan AN.   +3 more
europepmc   +1 more source

Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study. [PDF]

Ther Adv Musculoskelet Dis
Chen M, Lu L, Mao Y, Ji L, Xu J, Chen J, Zhu Y, Yuan J, Chen L, Yu J, Lu Q.   +10 more
europepmc   +1 more source

Efficacy and safety of zoledronic acid versus denosumab in the treatment of primary osteoporosis: a single-center retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Li X, Huang K, Zhang L, Shi Y, Zhao J, Li X, Gao J, Zhao D, Wan W.   +8 more
europepmc   +1 more source

Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. [PDF]

Yonsei Med J
Kuwabara A, Inage K, Yamashita M, Orita S, Eguchi Y, Shiga Y, Inoue M, Suzuki-Narita M, Hishiya T, Okuyama K, Tashiro S, Ohyama S, Suzuki N, Iida A, Otake Y, Ohtori S.   +15 more
europepmc   +1 more source

Age-related differences in BMD response during three years of denosumab treatment. [PDF]

Front Aging
Ishikawa K, Asada T, Richardson W, Marius C, Ishikawa M, Nguyen T, Varnadore P, Tani S, Passias P, Alman BA.   +9 more
europepmc   +1 more source

Long-term effects of denosumab: a 10-year single-center retrospective study. [PDF]

Arch Osteoporos
Aldegheri F, Appoloni M, Passoni N, Zibordi V, Rossini M, Gatti D, Adami G, Pollastri F, Fassio A, Viapiana O.   +9 more
europepmc   +1 more source

Keeping bone resorption markers very low for 1 year after denosumab prevents bone loss at 2 years: the ReoLaus study. [PDF]

Arch Osteoporos
Liebich G, Lamy O, Pasquier J, Gonzalez-Rodriguez E.   +3 more
europepmc   +1 more source

Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction. [PDF]

J Bone Oncol
Massy E, Stacoffe N, Fauvernier M, Duruisseaux M, Grolleau E, Lamkhioued M, Pérol M, Domblides C, Roche M, Stuani A, Clézardin P, Bonnelye E, Pialat JB, Girard N, Confavreux C.   +14 more
europepmc   +1 more source

Impact of denosumab therapy on periapical healing following root canal treatment: a 10-year retrospective case-control study. [PDF]

BMC Oral Health
Shin B, Yoon JY, Yoo YJ, Shon WJ.
europepmc   +1 more source

Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. [PDF]

Arch Osteoporos
Hare K, Wheeler S, Morganti C, Krueger D, Kimmel D, Binkley N.   +5 more
europepmc   +1 more source